Healthcare entity
All 1 tracked stories fall under one category: market-trends. Ollin is most often covered alongside Dr. Michael Yu, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Ollin appears in 1 tracked Healthcare story from August 25, 2026.
Last mentioned: Aug 25, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Ollin is most often covered alongside Dr. Michael Yu, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Ollin appears in 1 tracked Healthcare story from August 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ollin. Shared-story counts are live from our verified record — not editorial picks.
2026 interim results and 2030 vision announced
Innovent announces strong H1 2026 growth and sets a new strategic goal to become a global premier biopharma.
Revenue surpasses RMB 10 billion
Innovent reports full-year revenue over RMB 10 billion and full-scale profitability.
Global partnership wave begins
Over the next ten months, Innovent reaches collaborations with Takeda, Eli Lilly, Pfizer, Ollin, and Spero.
Second transformation begins
Innovent moves from a long-term investment phase toward full profitability and scale.
Full value-chain capability established
Innovent completes the first transformation spanning R&D, manufacturing, and commercialization.
First transformation begins
Innovent starts shifting from an R&D-driven biotech into a biopharmaceutical company with full value-chain capabilities.
Innovent's H1 2026 update signals a push from China regional champion to global biopharma with a 20+ asset partnered pipeline across oncology, autoimmune, cardiovascular/metabolic, and ophthalmology. Healthcare leaders should track how these global partnerships reshape care access and innovation.
Source: prnewswire.com · manilatimes.net
Ollin is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
